Table 6.
Estimated 3-year mean difference in change from baseline on handgrip strength in the three intervention groups compared with the control group (95% CI).
| ω3-PUFA vs. Placebo Mean (n; 95% CI) | Raw p Value (within Sub-Group Intervention vs. Placebo) | Adjusted p Value * (within Sub-Group Intervention vs. Placebo) | ω3-PUFA + Multidomain Intervention vs. Placebo Mean (n; 95% CI) | Raw p Value (within Sub-Group Intervention vs. Placebo) | Adjusted p Value * (within Sub-Group Intervention vs. Placebo) | Multidomain Intervention + Placebo vs. Placebo Mean (n; 95% CI) | Raw p Value (within Sub-Group Intervention vs. Placebo) | Adjusted p Value * (within Sub-Group Intervention vs. Placebo) | |
|---|---|---|---|---|---|---|---|---|---|
| Low DHA and EPA in red blood cells † | 0.423 (106; −1.564 to 2.410) | 0.676 | 0.845 | 0.206 (101; −1.740 to 2.153) | 0.835 | 0.845 | −0.202 (86; −2.236 to 1.832) | 0.8455 | 0.845 |
| Normal DHA and EPA in red blood cells † | 0.324 (287; −0.770 to 1.418 | 0.561 | 0.974 | −0.018 (287; −1.112 to 1.076) | 0.974 | 0.974 | −0.137 (287; −1.216 to 0.942) | 0.9740 | 0.803 |
| High adherent to the Multidomain intervention (at least 75% of the sessions) | 0.220 (335; −0.824 to 1.264) | 0.425 | 0.447 | −0.178 (59; −1.211 to 0.855) | 0.447 | 0.447 | −0.254 (354; −1.273 to 0.766) | 0.3964 | 0.396 |
| Low adherent to the Multidomain intervention (less than 75% of the sessions) | 1.769 (65; −0.658 to 4.196) | 0.152 | 0.458 | 0.669 (340; −1.830 to 3.167) | 0.599 | 0.599 | 1.122 (53; −1.473 to 3.716) | 0.3964 | 0.5997 |
BMI, Body Mass Index; MMSE, Mini-Mental State Examination; SPPB, Short Physical Performance Battery. A positive value of change is in favor of the intervention, whereas a negative value is in favor of the placebo. DHA = docosahexaenoic acid. EPA = eicosapentaenoic acid. * Adjusted for multiple comparisons with the Hochberg procedure to account for the fact that three intervention groups were compared with the placebo group in each analysis; † Low concentrations of DHA and EPA were defined by the lowest quartile of DHA plus EPA percentage at baseline in the modified intention-to-treat population (i.e., 4.83); SD, Standard Deviation.